Kyongbo Pharmaceutical Co Ltd
KRX:214390
Kyongbo Pharmaceutical Co Ltd
KRX:214390
Price:
7 150
KRW
-9.95%
Market Closed
Market Cap:
₩171B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Kyongbo Pharmaceutical Co Ltd
KRX:214390
|
KR |
|
A
|
AJ Advance Technology PCL
SET:AJA
|
TH |
|
A
|
ARB Bhd
KLSE:ARBB
|
MY |
|
National Aluminium Co Ltd
NSE:NATIONALUM
|
IN |
|
Comptoir Group PLC
LSE:COM
|
UK |
|
Mutual Corp
TSE:2773
|
JP |
|
Bitfarms Ltd
XTSX:BITF
|
CA |
|
enCore Energy Corp
XTSX:EU
|
CA |
|
T
|
T T Ltd
NSE:TTL
|
IN |
|
Shree Cement Ltd
BSE:500387
|
IN |
|
Nichiha Corp
TSE:7943
|
JP |
|
P
|
Perpetual Resources Ltd
ASX:PEC
|
AU |
|
Granite Real Estate Investment Trust
TSX:GRT.UN
|
CA |
Relative Value
The Relative Value of one
Kyongbo Pharmaceutical Co Ltd
stock under the Base Case scenario is
hidden
KRW.
Compared to the current market price of 7 150 KRW,
Kyongbo Pharmaceutical Co Ltd
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Kyongbo Pharmaceutical Co Ltd Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Kyongbo Pharmaceutical Co Ltd Competitors
Kyongbo Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| KR |
|
Kyongbo Pharmaceutical Co Ltd
KRX:214390
|
170.9B KRW | 0.6 | 937.7 | 17.4 | 82.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD | 13.2 | 41.8 | 28.2 | 30.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD | 6 | 21.2 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 3.9 | 18.6 | 11.1 | 12.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.5B GBP | 4.9 | 28 | 15.6 | 21.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.4 | 15.7 | 9.7 | 11.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 5.1 | 20.6 | 12.8 | 16.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD | 2.4 | 16.4 | 6.9 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
